Terms: = Kidney tumors AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Staging
3 results:
1. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma.
Saal J; Bald T; Eckstein M; Ralser DJ; Ritter M; Brossart P; Grünwald V; Hölzel M; Ellinger J; Klümper N
JAMA Oncol; 2023 Aug; 9(8):1048-1055. PubMed ID: 37347489
[TBL] [Abstract] [Full Text] [Related]
2. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
[TBL] [Abstract] [Full Text] [Related]
3. Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems.
Huo TI; Hsia CY; Huang YH; Lin HC; Lee PC; Lui WY; Chiang JH; Chiou YY; Loong CC; Lee SD
J Clin Gastroenterol; 2009 Sep; 43(8):773-81. PubMed ID: 19262404
[TBL] [Abstract] [Full Text] [Related]
